Bristol Myers Squibb (BMS) has shared positive five-year results from a long-term extension (LTE) study of its oral TYK2 ...
GlobalData on MSN1d
Bristol Myers Squibb’s Sotyktu shows consistent safety profile in psoriasis trialUS-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) ...
Bristol Myers Squibb today announced the Phase III RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) ...
Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis: Princeton, New Jersey Tuesday, February 18, 2025, 1 ...
Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this ...
Squibb announced new five-year results from the POETYK PSO long-term extension trial of Sotyktu treatment in adult patients ...
Bristol Myers Squibb said it is disappointed with the outcome of a study that examined whether one of its drugs could be used to treat a certain type of skin cancer. The drug, Opdualag, didn't meet ...
A Bristol Myers Squibb immunotherapy currently approved ... clinical study results were not released, but Jeffrey Walch, vice president, Opdualag global program lead at BMS, offered a possible ...
Christopher Boerner; Chairman of the Board, Chief Executive Officer, Chief Operating Officer; Bristol-Myers Squibb Co David Elkins; Executive Vice President, Chief Financial Officer, Member of the ...
Bristol-Myers Squibb (NYSE:BMY) reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback